Clinical Trials


Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

This study has been completed

Information provided by (Responsible Party)
Viriom Identifier

First received: October 11, 2018
Last updated: October 29, 2018
Last Verified: October 2018
History of Changes


Open-label, randomized, parallel-group, comparative study of pharmacokinetics and bioequivalence of VM-1500FDC (elsulfavirine/emtricitabine/tenofovir fixed-dose combination) and Elpida® with Truvada® (emtricitabine/tenofovir) co-administered by healthy male subjects. The study will also assess safety profile of study drugs.

Condition Intervention Phase

Drug : VM-1500FDC
Drug : Elpida®
Drug : Truvada®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Open-Label, Randomized, Parallel-group, Comparative Study of Pharmacokinetics and Bioequivalence of VM-1500FDC (Viriom Ltd, Russia) and Elpida® (Viriom Ltd, Russia) and Truvada® (Gilead Sciences Ireland UC, UK) When сo-administrated Once Daily Fasting in Healthy Subjects

Further study details as provided by Viriom:

Primary Outcome Measures

  • Plasma concentration of VM1500A [ Time Frame: 29 days ]
  • Plasma concentration of elsulfavirine [ Time Frame: 29 days ]
  • Plasma concentration of emtricitabine [ Time Frame: 29 days ]
  • Plasma concentration of tenofovir [ Time Frame: 29 days ]
Secondary Outcome Measures:
  • Frequency and severity of AEs and SAEs [ Time Frame: 29 days ]
    Frequency and severity of AE, recorded after administration of the drug according to subjective complaints, changes in vital signs, ECG, laboratory results and physical examination compared to the baseline

Enrollment: 140
Study Start Date: June 1, 2018
Study Completion Date: October 12, 2018
Primary Completion Date: October 12, 2018 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: VM-1500FDC
VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
Drug: VM-1500FDC

A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets

Other Name: VM1500FDC
Active Comparator: Elpida® & Truvada®
Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
Drug: Elpida®

Elpida®, capsules, elsulfavirine 20 mg

Other Name:
  • VM-1500
  • VM1500
  • Elsulfavirine

Drug: Truvada®

Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets

Detailed Description:

The study assesses PK and bioequivalence of the developed new drug VM-1500FDC - a fixed combination of three active substances: elsulfavirine (NNRTI), emtricitabine (NRTI) and tenofovir (NRTI) to Elpida® and Truvada® co-administered. The combination is intended for once daily administration (1 tablet) for the treatment of HIV-1 infection in adult patients. Thus, the purpose of this combination is to simplify the dosage regimen and improve patient compliance



Ages Eligible for Study: 20 Years to 40 Years  
Sexes Eligible for Study: Male  
Accepts Healthy Volunteers: Yes  


Inclusion Criteria:

    1. Non-smoking male subjects between the ages of 20 and 40 years (inclusive);
    2. Verified diagnosis of "healthy" according to standard clinical, laboratory and instrumental examination methods;
    3. Body weight from 60 to 95 kg and Body Mass Index from 19.0 to 27.0 kg/m;
    4. A negative result in tests for alcohol and drugs;
    5. The subject's consent to use adequate contraception methods during the study and 3 month after end of study: condom with spermicide (foam, gel, cream, suppositories);
    6. Signed the Participant Explanation Sheet and the Informed Consent Form.

Exclusion Criteria:
    1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood;
    2. Variables of standard laboratory and instrumental parameters are beyond the normal limits Variables of standard laboratory and instrumental parameters are beyond the normal limits (taking into account the acceptable limits of laboratory parameters);
    3. Surgical interventions on the gastrointestinal tract in medical history (except appendectomy);
    4. Systolic pressure less than 90 mm Mercury or above 130 mm Mercury, diastolic pressure less than 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more than 90 BPM at screening;
    5. Regular intake of drugs less than 2 weeks prior to screening (including herbal preparations and dietary supplements); intake of drugs that have a pronounced effect on hemodynamics, liver function, etc. (for example, barbiturates, omeprazole, cimetidine, etc.) less than 30 days prior to screening;
    6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface antigen, a positive syphilis test;
    7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent return from another time zone, etc.), extreme physical activity (e.g. weight lifting), a special diet (e.g. vegetarian, vegan);
    8. Signs of alcohol (taking more than 10 units of alcohol per week ) or drug addiction; alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3 months prior to screening; positive drug and/or alcohol test;
    9. Burdened allergic medical history (including drug intolerance and food allergy);
    10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
    11. Hypersensitivity to tenofovir, elsulfavirine or emtricitabine, as well as any other component of the study drugs;
    12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to screening;
    13. Treatment with a study drug in framework of other clinical trials within 30 days prior to screening (including follow-up visits);
    14. Acute infectious diseases less than 4 weeks prior to screening;
    15. Incapable of reading or writing; no desire to understand and adhere to the study
    protocol procedures; non-compliance with the drugs intake regimen or execution of procedures, which as the Investigator may think may affect the study results or subject's safety and prevent the subject from further participation in the study; any other associated medical or serious psychological conditions making the subject not eligible to participate in the clinical study, restricting legality of obtaining the informed consent or affecting the subject's ability to take part in the study.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03706924


Russian Federation
Central City Clinical Hospital Reutov
Reutov, Moscow Region, Russian Federation, 143965
Private non - governmental health care institution "Scientific Clinical Center of the open joint - stock company Russian Railways"
Moscow, Russian Federation, 125315

Sponsors and Collaborators



Principal Investigator: Elena Mazygula, PhD Private non - governmental health care institution "Scientific Clinical Center of the open joint - stock company Russian Railways"
More Information

More Information

Responsible Party: Viriom Identifier: NCT03706924   History of Changes  
Other Study ID Numbers: HIV-VM1500FDC-01  
Study First Received: October 11, 2018  
Last Updated: October 29, 2018  
Individual Participant Data    
Plan to Share IPD: No  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by Viriom:

HIV -1
elsulfavirine fixed-dose combination

Additional relevant MeSH terms:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination processed this data on May 28, 2020
This information is provided by